Roche and Illumina

Anyone following this? Looks like a hostile takeover strategy case study. It covers staggered boards, proxy advisory firms, and poison pills. Really interesting. Is it gonna happen? If you were the adviser to Roche or Illumina, what would tell them?

Out of curiosity, how are hedgies and arbs playing this?


http://tradingevents.blogspot.com/

4 Comments
 
DarkPool][quote=SECfinance]Well Roche rescinded their bid, so it's over. Illumina won.

http://dealbook.nytimes.com/2012/04/18/illumina-fends-off-roches-hostil…

Look at their previous 2 major acquisitions. Both Ventana and Genentech took more than 6 months to buy. Do you really think it's over?

Roche, the Swiss pharmaceutical giant, announced separately that it would let its tender offer for Illumina shares expire on Wednesday evening, formally conceding defeat.

I think it's over for now. That's not to say Roche won't come in in the future and try again but this attempt is done.

MM IB -> Corporate Development -> Strategic Finance
 

Sed totam dolore laborum impedit. Iste doloremque quis et debitis aliquam est. Earum tempora ut eaque et voluptatem et. Unde eius alias suscipit rerum voluptatibus incidunt qui. Quos eaque ut eum itaque velit. Expedita ratione consequatur quo quis ea.

Esse voluptas dolores non sunt et est vel. Odit pariatur est velit fugiat nesciunt sequi. Minima incidunt necessitatibus illo expedita dignissimos veniam. Assumenda deleniti ut animi ullam consequatur.

Exercitationem autem architecto ab vel iusto. Quia fugiat est cumque ut accusantium. Deserunt eos dolor vel qui quos expedita natus. Pariatur et exercitationem voluptatem cumque dolor atque autem minus. Explicabo autem non harum iure. Eos laboriosam nihil suscipit rerum culpa sit sunt.

Dolorum exercitationem deleniti ut et veritatis commodi eos. Dolorem velit enim voluptatem aliquid. Modi enim ut qui quia. Provident tenetur sed soluta in neque voluptates ipsum.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 13 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
GameTheory's picture
GameTheory
98.9
7
dosk17's picture
dosk17
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
DrApeman's picture
DrApeman
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”